title: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
abstract: OBJECTIVE
  To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL).
  
  
  METHODS
  A total of 38 CLL patients received a matched URD transplant using bone marrow procured by the National Marrow Donor Program. The median age was 45 years (range, 26 to 57 years), the median time from diagnosis was 51 months, and the median number of prior chemotherapy regimens was three. Fifty-five percent of patients were chemotherapy refractory and 89% had received fludarabine. Conditioning included total-body irradiation in 92% of patients. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82% of patients.
  
  
  RESULTS
  Twenty-one patients (58%) achieved complete response and six (17%) achieved partial response. Incidences of grades 2 to 4 acute GVHD were 45% at 100 days and incidences of chronic GVHD were 85% at 5 years. Eleven patients are alive and disease free at a median of 6 years (range, 3.0 to 9.0 years). Five-year overall survival, failure-free survival, disease progression rates, and treatment-related mortality (TRM) were 33%, 30%, 32%, and 38% respectively.
  
  
  CONCLUSIONS
  These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL. High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols, and it is mandatory to investigate transplant strategies with a lower morbidity and mortality, including the use of nonmyeloablative regimens.
authors.affiliation: Graft-versus-Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room CRC 3-3330, Bethesda, MD 20892-1907, USA. pavletis@mail.nih.gov
authors.forename: Steven Z
authors.initials: SZ
authors.lastname: Pavletic
authors.forename: Issa F
authors.initials: IF
authors.lastname: Khouri
authors.forename: Michael
authors.initials: M
authors.lastname: Haagenson
authors.forename: Roberta J
authors.initials: RJ
authors.lastname: King
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
authors.forename: Michael
authors.initials: M
authors.lastname: Carston
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Edward A
authors.initials: EA
authors.lastname: Copelan
authors.forename: Olle
authors.initials: O
authors.lastname: Ringdén
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
authors.forename: Karen
authors.initials: K
authors.lastname: Ballen
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Adkins
authors.forename: Philip
authors.initials: P
authors.lastname: McCarthy
authors.forename: Daniel
authors.initials: D
authors.lastname: Weisdorf
authors.forename: Emili
authors.initials: E
authors.lastname: Montserrat
authors.forename: Claudio
authors.initials: C
authors.lastname: Anasetti
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome